大冢VOYXACT两年eGFR数据显著稳定IgA肾病肾功能，但亚太映射已缺少可执行边际

# 美股盘后催化 9/12: Otsuka Voyxact两年eGFR数据显著稳定IgA肾病肾功能，传统批准sBLA证据增强

- 美股会话: 2026-08-03
- 方向: POSITIVE；类型: 产品/技术；规划重大性: 7/10
- 映射模式: competitive
- 美股驱动（规划器初判，需独立核验）: 事实：Otsuka公布Phase 3 VISIONARY两年数据，sibeprenlimab年化eGFR斜率为+0.3，对照组为-4.2，治疗差异+4.5且p<0.0001，安全性与安慰剂相当、无新增安全信号。推断：该数据提高Voyxact从加速批准走向传统批准的概率，并可能抬高IgAN治疗长期肾功能终点证据标准。

## 本催化相关美股真实收盘行情

- VRTX.US (VRTX.US): 470.72 -1.34%

## 亚太映射假设（仅候选，必须查证）

- 大冢控股 (4578.JP) [JP/同源本地股/positive]: Otsuka为披露主体，强两年肾功能数据提升Voyxact传统批准和长期商业化可见度。；核验问题: 核实Voyxact当前销售、定价、传统批准时间表和Otsuka利润分成结构。
- 港股IgAN/自身免疫创新药公司 (TBD.HK) [HK/竞争替代/mixed]: APRIL抑制剂长期肾功能数据可能提高同适应症临床门槛，同时扩大IgAN市场关注。；核验问题: 筛选港股/A股IgAN、APRIL/BAFF、补体或肾病管线公司，并比较终点、阶段和地区权益。

## 必答问题

- VERA、VRTX相关IgAN资产与Voyxact在机制、终点和上市时间上如何竞争？
- 传统批准sBLA是否已有FDA明确审评时间表？
- 亚洲IgAN管线是否需要重新下调或上调成功概率？

## 原始证据全文（2 条）

### [E2897] Adam Feuerstein (STAT) | 2026-08-03 21:58 UTC | 收盘后
Otsuka presented the two-year EGFR results from its pivotal study of Voyxact. The data have bearing on $VERA and $VRTX

Results presented during a late-breaking oral presentation at the GlomCon Hawaii 2026 conference showed the study achie
URL: https://x.com/adamfeuerstein/status/2084398599979364812
Otsuka presented the two-year EGFR results from its pivotal study of Voyxact. The data have bearing on $VERA and $VRTX

Results presented during a late-breaking oral presentation at the GlomCon Hawaii 2026 conference showed the study achieved its key secondary endpoint, with an annualized eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/year with sibeprenlimab versus -4.2 (95% CI, -4.9 to -3.6) mL/min/1.73 m²/year with placebo, demonstrating a statistically significant treatment effect of +4.5 (95% CI, 3.6 to 5.4; p<0.0001) mL/min/1.73 m²/year at two years (24 months).

### [E2904] 4578 大冢控股 | 2026-08-04 00:00 UTC | 收盘后
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
URL: https://www.otsuka.co.jp/en/company/newsreleases/2026/20260804_2.html
Otsuka Pharmaceutical Co., Ltd.
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy
- Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/year with sibeprenlimab versus -4.2 (95% CI, -4.9 to -3.6) mL/min/1.73 m²/year with placebo
- VOYXACT is the first-and-only U.S. FDA-approved IgAN treatment to show stabilization of kidney function, with evidence of improvement, and a safety profile consistent with placebo over two years
- Adds to clinical evidence confirming VOYXACT's selective APRIL inhibition as a disease-modifying therapeutic approach that targets a key IgAN driver to halt disease progression
- New findings complete the Phase 3 VISIONARY study, marking another milestone in Otsuka's rolling submission of a supplemental Biologics License Application (sBLA) to the U.S. FDA for traditional approval of VOYXACT
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT® (sibeprenlimab-szsi) stabilizes estimated glomerular filtration rate (eGFR) returning kidney function decline to baseline physiologic rate over two years (24 months) in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Results presented during a late-breaking oral presentation at the GlomCon Hawaii 2026 conference showed the study achieved its key secondary endpoint, with an annualized eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/year with sibeprenlimab versus -4.2 (95% CI, -4.9 to -3.6) mL/min/1.73 m²/year with placebo, demonstrating a statistically significant treatment effect of +4.5 (95% CI, 3.6 to 5.4; p<0.0001) mL/min/1.73 m²/year at two years (24 months). VOYXACT is the first IgAN treatment to achieve the KDIGO therapeutic goal of effectively halting progressive kidney function decline to physiologic rate (<1 mL/min/1.73 m²/year for most adults)1. The overall safety profile of sibeprenlimab remained consistent through two years (24 months) and was comparable to placebo, with similar rates of overall adverse events (90.7% vs 90.0%), infections and infestations (51.4% vs 51.0%), and injection site reactions (35.1% vs 32.2%). No new safety signals were identified, and rates of serious infections were lower with sibeprenlimab than placebo (1.9% vs 4.0%), alongside lower rates of serious and severe adverse events and treatment discontinuations. A complete analysis of the Phase 3 VISIONARY two-year (24-month) results will be presented at an upcoming scientific congress.
"For nephrologists, stabilization of kidney function in IgAN patients represents a major advancement in the clinical management of this disease," said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham and VOYXACT VISIONARY study site principal investigator and co-chair of the steering committee. "The VISIONARY two-year eGFR results achieved the KDIGO treatment goal of reducing kidney function decline to near physiological level, fundamentally altering the disease progression. The magnitude and consistency of benefit across pre-specified sub-groups, coupled with the reassuring safety profile of VOYXACT, delivers new hope for better long-term outcomes in patients living with this progressive condition."
The annualized eGFR slope (the study's key secondary endpoint) was estimated using a prespecified linear mixed-effects model that evaluated repeated eGFR measurements from Week 4 through Week 104 (24 months) to estimate the annual rate of kidney function change. At two years (24 months), the least square mean change from baseline in eGFR showed +1.3 mL/min/1.73 m² with sibeprenlimab (95% CI, −0.3 to 2.8), compared with −7.9 mL/min/1.73 m² with placebo (95% CI, −9.5 to −6.4), for a treatment difference of +9.2 mL/min/1.73 m² (95% CI, 7.1 to 11.4; p<0.0001). The least square mean change from baseline in eGFR at two years (24 months) was evaluated as a complementary secondary endpoint and was analyzed using a Mixed Model for Repeated Measures (MMRM) to assess the overall difference in kidney function from study entry to the two-year (24-month) timepoint.
"The VISIONARY trial provides the largest Phase 3 study in IgAN, with 24 months of follow-up in a broad, representative, patient population reflective of real-world clinical practice," said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, OPDC. "These transformative results deliver the largest treatment effect reported in a Phase 3 IgAN trial, with a magnitude of benefit demonstrating stabilization of kidney function and halting of disease progression beyond symptom management, with the potential to redefine the treatment landscape. This data adds to the body of evidence supporting selective APRIL inhibition as a safe, durable and disease-modifying therapeutic approach that targets underlying IgAN drivers."
Otsuka would like to thank the patients, families, advocates, and investigators who participated in the Phase 3 VISIONARY trial, and who continue to advance IgAN research with the shared goal and persistent pursuit of delivering breakthroughs on patients' behalf.
VOYXACT is the first-and-only U.S. FDA-approved selective A-PRoliferation-Inducing-Ligand (APRIL) inhibitor, offering an early, targeted therapy that addresses key drivers of IgAN to alter disease progression2. VOYXACT was granted accelerated approval by the U.S. FDA in November 2025 after meeting the Phase 3 VISIONARY study's primary endpoint of statistically significant proteinuria reduction compared to placebo at nine months. VOYXACT was well tolerated, with a favorable safety profile comparable to placebo. The two-year eGFR results build on previously observed reductions in Gd-IgA1, proteinuria, and hematuria, underscoring VOYXACT's ability to modify the disease and improve long-term clinical outcomes in IgAN2. These new findings complete the Phase 3 VISIONARY study dataset, marking another milestone in Otsuka's rolling submission of a supplemental Biologics License Application (sBLA) to the U.S. FDA for VOYXACT traditional approval.
About the VISIONARY Study
VISIONARY (NCT05248646) is a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of VOYXACT (sibeprenlimab-szsi) in adults with primary IgAN at risk for disease progression. The primary efficacy endpoint assessed proteinuria reduction, as measured by the change in 24-hour urine protein-to-creatinine ratio (uPCR-24h) from baseline compared with placebo after nine months of treatment. The key secondary endpoint evaluates annualized eGFR slope over 24 months (two years), providing an assessment of kidney function over time. The least square mean change from baseline in eGFR at month 24 was also evaluated as a secondary endpoint, offering a complementary measure of overall treatment effect at a defined timepoint1,2. This program continues to advance the science in IgAN, with future data forthcoming in an open-label, long-term extension study (NCT05248659).
About IgAN
IgA nephropathy (IgAN) is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and can lead to kidney failure (KF) over the lifetime of most patients3-5. IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys7. IgAN can lead to progressive loss of kidney function and, eventually, KF, imposing a significant burden on patients5. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition6. Continued research in IgAN remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients6.
About VOYXACT® (sibeprenlimab-szsi)
VOYXACT (sibeprenlimab-szsi) is a humanized monoclonal antibody that binds to and blocks APRIL, which plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic galactose-deficient IgA1 (Gd-IgA1)2,6,7. Inhibition of APRIL results in reduced levels of serum galactose-deficient IgA1 (Gd-IgA1), which is implicated in the pathogenesis of IgAN. VOYXACT is a self-administered, subcutaneous injection dosed once every four weeks. VOYXACT is the first-and-only U.S. FDA-approved treatment for adults with primary IgAN at risk for disease progression that selectively inhibits APRIL, a key immune driver of the disease2. VOYXACT is the only U.S. FDA-approved selective APRIL inhibitor to demonstrate stabilization of eGFR compared with placebo over two years. VOYXACT was granted accelerated approval by the U.S. FDA on November 25, 2025. Otsuka has initiated a rolling submission of an sBLA to the U.S. FDA for VOYXACT traditional approval, which will include the 24-month (two-year) eGFR findings.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide.
For further information, please visit www.otsuka.co.jp/en/
- 1
- Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71.
- 2Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., Jha, V., Quevedo, A., Han, S. H., Praga, M., Chacko, B., Sahay, M., Cheung, C. K., Kooienga, L., Walsh, M., ... Rizk, D. V. (2026). Sibeprenlimab in IGA nephropathy -- interim analysis of a phase 3 trial. New England Journal of Medicine, 394(7), 635-646.https://doi.org/10.1056/nejmoa2512133
- 3Pitcher, D. Braddon, et. al Long-term outcomes in IGA nephropathy. Clinical journal of the American Society of Nephrology: CJASN. https://pubmed.ncbi.nlm.nih.gov/37055195/
- 4 Cheung, Chee Kay & Boyd, JKF & Feehally, J.. (2012). Evaluation and management of IgA nephropathy. Clinical Medicine. 12. s27-s30. 10.7861/clinmedicine.12-6-s27.
- 5 Lai K. Iga nephropathy. Nature reviews. Disease primers. 2016
- 6 Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and April in IGA nephropathy: Pathogenic mechanisms and targeted therapies. Frontiers in nephrology. February 1, 2024.
- 7 Chang S, Li XK. The Role of Immune Modulation in Pathogenesis of IgA Nephropathy (nih.gov)

## 研究交付要求

这是一条已经从整场材料语义拆出的独立催化，不要重新把它压回大盘总评。核实美股异动原因和传播时序；用结构化供应链、内部 KB 与公司披露坐实每个亚洲候选；逐腿查真实行情和本地市场 price-in；候选不成立也要逐条给出有证据的 AVOID。